Hualan Biological Vaccine Inc. Stock Analysis 301207.SZ

Hualan Biological Vaccine, Inc. engages in research and development, production and sales of human vaccines. The company is headquartered in Xinxiang, Henan and currently employs 708 full-time employees. The company went IPO on 2022-02-18. The firm's main product is human vaccines, including influenza virus split vaccines, quadrivalent influenza virus split vaccines, quadrivalent influenza virus split vaccines (Children's dosage form), H1N1 influenza virus split vaccines, ACYW135 meningococcal polysaccharide vaccines, recombinant hepatitis B vaccines (Hansenula), A and C meningococcal polysaccharide vaccines, freeze-dried human rabies vaccines (Vero cells), and adsorbed tetanus vaccines, and others. The Company’s products cover viral vaccines, bacterial vaccines, and genetically recombinant vaccines. The firm mainly operates its businesses in the domestic market.